Japan's largest pharma company, Takeda Pharmaceutical (TSE: 4502), has announced two deals with USA-based biotech firms in as many days.
On Thursday, the company announced the creation of a new development partnership with Cardurion, a recently-launched biotech focused on the development of next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases.
Takeda will jumpstart the new company’s discovery efforts by providing a 12-person cardiovascular research team from a site in Shonan, Japan, including development resources and licenses to a portfolio of preclinical-stage cardiovascular drug programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze